 |
|||||||||||||||
|
|
|||||||||||||||
|
 |
|||
| ID | Site | Study Title | Status |
| IND.215 | Phase Ib | A Phase Ib Study of Selumetinib in Patients with Previously Treated or Untreated Advanced/ Metastatic NSCLC Who are Receiving Standard Chemotherapy Regimens MORE... |
Cohort 1: Open Cohort 2: Open Cohort 3: Planned |
| IND.213 | Phase II | A Randomized Phase II Study of Reolysin For Patients Receiving Standard Weekly Paclitaxel Therapy as Therapy For Advanced/Metastatic Breast Cancer MORE... | Open |
| IND.212 | Phase I | A Pilot Study of Imetelstat given Intravenously on Day 1 and 8 of a 21 Day Schedule Alone and With Standard 13-Cis-Retinoic Acid in Children with Recurrent and/or Refractory Neuroblastoma MORE... | Planned |
| IND.211 | Phase II | A Randomized Phase II Study of Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy MORE... | Open |
| IND.210 | Phase II | A Randomized Phase II Study of Reolysin in Combination with FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Patients with Metastatic Colorectal Cancer MORE... | Open |
| IND.209 | Phase II | A Randomized Phase II Study Of Reolysin® in Combination With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in patients With Metastatic Castration Resistant Prostate Cancer MORE... | Open |
| IND.208 | Phase I/II | Phase I/II Study of the P13Kinase Inhibitor BKM120 Given in Combination with Panitumumab in Patients with Metastatic or Advanced RAS-Wild Type Colorectal Cancer MORE... | Open |
| IND.207 | Phase II | A Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma MORE... | Open |
| IND.206 | Phase II | A Phase II Study of Sunitinib or Temsirolimus in Patients with Advanced Rare Tumours MORE... | Open |
| IND.205 | Phase II | A Phase II Study of PX-866 in Patients With Metastatic Castration Resistant Prostate Cancer (CRPC) MORE... |
Part A - Closed Part B -Open |
| IND.204 | Phase II | A Phase II Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression MORE... | Closed |
| IND.203 | Phase I | A Phase I Study of SB939 in Pediatric Patients with Refractory Solid Tumours and Leukemia MORE... | Closed |
| IND.202 | Phase II | A Randomized Phase II Study of Interleukin-21 (rIL-21) versus Dacarbazine (DTIC) in Patients with Metastatic or Recurrent Melanoma MORE... | Closed |
| IND.200 | Phase II | A Phase II Study of SB939 in Patients with Translocation-Associated Recurrent/Metastatic Sarcomas MORE... | Closed |
| IND.199 | Phase II | A Phase II Study of Temsirolimus (NSC 683864), an mTOR Inhibitor, in Patients with Recurrent, Unresectable, Locally Advanced or Metastatic Carcimona of the Cervix MORE... | Closed |
| IND.198 | Phase I/II | A Phase I/II Study of Foretinib in Combination with Lapatinib in Patients with Human Epidermal Growth Factor Receptor (HER2) Over-Expressing Metastatic Breast Cancer MORE... | Closed |
| IND.197 | Phase II | A Phase II Study of Foretinib in Patients with Estrogen Receptor (ER), Progesterone Receptor (PR) and Human Epidermal Growth Factor Receptor 2 (HER2) Negative, Recurrent/Metastatic Breast Cancer MORE... | On Hold |
| IND.196 | Phase I/II | A Phase I/II Study of Foretinib in Patients with Previously Treated Non-Small Cell Lung Cancer Receiving Standard Erlotinib Therapy MORE... | Closed |
| IND.195 | Phase II | A Phase II Study of SB939 in Patients with Recurrent or Metastatic Castration Resistant Prostate Cancer MORE... | Closed |
| IND.194 | Phase II | A Phase II Study of AT7519M, a CDK Inhibitor, in Patients with Relapsed Mantle Cell Lymphoma MORE... | Open |
| IND.193 | Phase II | A Phase II Study of AT7519M, A CDK Inhibitor in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia MORE... | Open |
| IND.192 | Phase II | A Phase II Study of Ridaforolimus in Patients with Metastatic and/or Locally Advanced Recurrent Endometrial Cancer MORE... | Closed |
| IND.191 | Phase II | A Phase II Study of AT9283 in Patients with Relapsed or Refractory Multiple Myeloma MORE... | Closed |
| IND.190 | Phase I/II | A Phase I-II Trial of MK-0646, a Monoclonal Antibody Against Insulin-Like Growth Factor-1 Receptor in Combination with Etoposide and Cisplatin in Extensive Stage Small Cell Lung Cancer MORE... | Permanently Closed |
| IND.189 | Phase II | A Phase II Study of Interlukin-21 (Il-21) in Patients with Metastatic or Recurrent Malignant Melanoma MORE... | Permanently Closed |
| IND.188 | Phase I | A Clinical and Pharmacokinetic Study of Sb939 in Patients with Advanced Cancer MORE... | Permanently Closed |
| IND.187 | Phase I | A Phase I Study Of AZD2281 In Combination With Irinotecan In Patients With Locally Advanced or Metastatic Incurable Colorectal Cancer MORE... | Closed |
| IND.186 | Phase I/II | A Phase I/II Study of Sorafenib (BAY 43-9006) In Combination With Low Dose ARA-C (Cytarabine) In Elderly Patients With AML Or High-Risk MDS MORE... | Permanently Closed |
| IND.185 | Gynecologic | A Phase II Study of Sunitinib (SU11248; NSC 736511) in Patients with Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma MORE... | Permanently Closed |
| IND.184 | Gynecologic | A Phase II Study of Sunitinib, an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Patients with Unresectable, Locally Advanced or Metastatic Cervical Carcinoma MORE... | Permanently Closed |
| IND.183 | Phase II | A Phase II Study of Sunitinib in Patients with Advanced Malignant Pleural Mesothelioma MORE... | Permanently Closed |
| IND.182 | Hematologic | A Phase II Study of Sunitinib (SU11248; NSC 736511; IND 74019), an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma MORE... | Permanently Closed |
| IND.181 | Phase I | NCIC CTG Phase I Study of AT9283 Given as a 24 Hour Infusion on Days 1 and 8 Every Three Weeks in Patients with Advanced Incurable Malignancy MORE... | Permanently Closed |
| IND.179 | Phase I | A Phase I Study of CCI-779 in Combination with Carboplatin and Paclitaxel in Patients with Advanced Solid Tumours MORE... | Permanently Closed |
| IND.178 | Phase I | A Phase I Dose-Escalation Study Of JX-963 (Thymidine Kinase/Vaccinia Growth Factor Gene-Deleted Vaccinia Virus Plus GM-CSF) In Patients With Advanced Incurable Solid Tumours MORE... | Closed |
| IND.177 | Phase I | A Phase I Study of AT7519M Given Twice Weekly in Patients with Advanced Incurable Malignancy MORE... | Permanently Closed |
| IND.175 | Phase I | A Phase I, Open-Label, Dose-Seeking Study of AZD2171 Given Daily Orally in Combination with Selected Standard Chemotherapy Regimens (CT) in Patients with Advanced Incurable Non-Small Cell Lung Cancer (NSCLC) or Colorectal Cancer MORE... | Permanently Closed |
| IND.173 | Phase I/II | A Phase I/II Study of AZD0530 in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer MORE... | Permanently Closed |
| IND.172 | Hematologic | Phase II Study of Bortezomib and Gemcitabine in Patients with Relapsed Mantle Cell Lymphoma MORE... | Permanently Closed |
| IND.171 | Phase I | A Phase I, Open-Label, Dose-Seeking Study of AZD2171 Given Daily Orally in Combination with Standard Chemotherapy Regimens (CT) in Patients with Advanced Incurable Non-Small Cell Lung Cancer (NSCLC) or Colorectal Cancer or Other Tumour Types Suitable for Treatment with Capecitabine MORE... | Permanently Closed |
| IND.170 | Phase I/II | A Phase I/II Study of GW572016 in Patients with Recurrent Malignant Glioma MORE... | Permanently Closed |
| IND.169 | Melanoma | This is a Non-Randomized, Non-Blinded Multicentre Phase II Study of SB-715992 in Previously Untreated Patients with Metastatic or Recurrent Malignant Melanoma MORE... | Permanently Closed |
| IND.168 | Phase II | SB-715992 (NSC 727990) in Patients with Locally Advanced, Recurrent or Metastatic Hepatocellular Carcinoma MORE... | Permanently Closed |
| IND.167 | Genito-Urinary | Phase II Study of BAY 43-9006 (NSC 724772) in Patients with Hormone Refractory Prostate Cancer MORE... | Permanently Closed |
| IND.166B | Phase I | This is a Multi-Centre, Open-Label, Dose-Escalating Phase I Clinical Trial of AEG35156 in Combination with Docetaxel in Patients with Solid Tumours MORE... | Permanently Closed |
| IND.166 | Phase I | This is a Multi-Centre, Open-Label, Dose-Escalating Phase I Clinical Trial of AEG35156 in Combination with Docetaxel in Patients with Solid Tumours MORE... | Permanently Closed |
| IND.165 | Genito-Urinary | A Randomized Phase II Study of OGX-011 in Combination with Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Patients with Metastatic Hormone Refractory Prostate Cancer MORE... | Permanently Closed |
| IND.164 | Breast | A Phase II Study of a Second Generation Clusterin Antisense Oligonucleotide (OGX-011) in Combination with Docetaxel in Advanced Breast Cancer MORE... | Permanently Closed |
| IND.163 | Breast | A Randomized Phase II Study of Two Different Schedules of RAD001C in Patients with Recurrent/Metastatic Breast Cancer MORE... | Permanently Closed |
| IND.162 | Phase I | A Phase I Study of Temozolomide and RAD001C in Patients with Malignant Glioma MORE... | Permanently Closed |
| IND.160 | Gynecologic | A Phase II Study Of CCI-779 in Patients with Metastatic and/or Locally Advanced Recurrent Endometrial Cancer MORE... | Permanently Closed |
| If you have any questions, comments or suggestions, please contact our |